Iron-Dextran Complex
ApprovedSmall molecule
Iron-Dextran Complex is one of 39 small molecule programs targeting Anemia. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
38
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
272 competitors in Anemia
#DrugCompanyPhaseTrials
1Soliris
AstraZenecaPhase 3
Omontys
TakedaPhase 3
Jesduvroq
GGlaxo Dba Glaxosmithkline
Phase 3
Epoetin
RochePhase 3
Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Preclinical
Aranesp
AmgenPreclinical
Iron-Dextran Complex
OOregon Health and Science University
Approved
Desidustat
ZZydus Lifesciences Limited
Phase 3
Iron Sucrose Injection USP
WWatson Pharmaceuticals
Phase 3
HSK39297
Haisco Pharmaceutical Group Co., Ltd.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Iron-Dextran Complex. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details